Related references
Note: Only part of the references are listed.Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
William Kevin Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
Matthew R. Smith et al.
LANCET (2012)
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
R. Petrioli et al.
BRITISH JOURNAL OF CANCER (2011)
A Phase 2 Study of Estramustine, Docetaxel, and Bevacizumab in Men With Castrate-Resistant Prostate Cancer Results From Cancer and Leukemia Group B Study 90006
Joel Picus et al.
CANCER (2011)
Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)
C. Parker et al.
EUROPEAN JOURNAL OF CANCER (2011)
Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
M. Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
G. Sonpavde et al.
ANNALS OF ONCOLOGY (2010)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Horwich et al.
ANNALS OF ONCOLOGY (2010)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Kim N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Yang-Min Ning et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer
Tomihiko Yasufuku et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improvement in Sensory Pain Rating After Palliative Systemic Radionuclide Therapy in Patients With Advanced Prostate Cancer
Frank J. Papatheofanis et al.
AMERICAN JOURNAL OF THERAPEUTICS (2009)
Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer
Celestia S. Higano et al.
CANCER (2009)
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Lawrence Fong et al.
CANCER RESEARCH (2009)
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
Evan Y. Yu et al.
CLINICAL CANCER RESEARCH (2009)
Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
Nicholas D. James et al.
EUROPEAN UROLOGY (2009)
Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
Karim Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase 1/2 dose-escalation study of a GM-CSF-Secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
Celestial S. Higano et al.
CANCER (2008)
Phase 3, Randomized, Controlled Trial of Atrasentan in Patients With Nonmetastatic, Hormone-Refractory Prostate Cancer
Joel B. Nelson et al.
CANCER (2008)
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study
Dominik R. Berthold et al.
CLINICAL CANCER RESEARCH (2008)
Bisphosphonates in Hormone-Refractory Prostate Cancer: Do We Have a Toxicity Problem?
Noel W. Clarke
EUROPEAN UROLOGY (2008)
Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)
T. M. Beer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
Michael A. Carducci et al.
CANCER (2007)
Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer:: a randomised, multicentre, placebo-controlled phase II study
Sten Nilsson et al.
LANCET ONCOLOGY (2007)
Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro
Palma Rocchi et al.
BJU INTERNATIONAL (2006)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
JJ Body et al.
CLINICAL CANCER RESEARCH (2006)
Costimulatory molecules as adjuvants for immunotherapy
JW Hodge et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2006)
Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy - A comprehensive review
AS Sreedhar et al.
PHARMACOLOGY & THERAPEUTICS (2004)
Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer
P Rocchi et al.
CANCER RESEARCH (2004)
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
WL Dahut et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Single fraction radiotherapy is efficacious: A further analysis of the dutch bone metastasis study controlling for the influence of retreatment
YM van der Linden et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer
O Sartor et al.
UROLOGY (2004)
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma - Cancer and leukemia group B 99813
WK Oh et al.
CANCER (2003)
The endothelin axis: Emerging role in cancer
J Nelson et al.
NATURE REVIEWS CANCER (2003)
Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: A phase III study of the European Organisation for Research and Treatment of Cancer Genitourinary Group
GON Oosterhof et al.
EUROPEAN UROLOGY (2003)
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial
SM Tu et al.
LANCET (2001)
Share Paper
